Neurodegenerative diseases

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by degeneration of the dopamine neurons of the substantia nigra, resulting in disturbed planning and coordination of movements that seriously deteriorate quality of life. PD can be studied in common marmosets, based on MPTP-induced dopaminergic cell loss.
An array of computerized behavioral and neurophysiological tests has been developed for monitoring of the disease process; based on telemetry (home cage activity), touch screen (cognition tests) and EEG (sleep). The tests can be implemented in all neuropathology models.

Selected References

The MPTP marmoset model of parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseases
Philippens IH, 't Hart BA, Torres G.
Drug Discov Today. 2010 Dec;15(23-24):985-90.

Neurofeedback training on sensorimotor rhythm in marmoset monkeys.
Philippens IH, Vanwersch RA.
Neuroreport. 2010 Mar 31;21(5):328-32..

Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
Verhave PS, Jongsma MJ, Van Den Berg RM, Vanwersch RA, Smit AB, Philippens IH.
Neuropharmacology. 2012 Mar;62(4):1700-7.

17α-Ethynyl-androst-5-ene-3?,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease.
Nicoletti F, Philippens I, Fagone P, Ahlem CN, Reading CL, Frincke JM, Auci DL.
Parkinsons Dis. 2012;2012:969418

Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.
Philippens IH, Wubben JA, Finsen B, 't Hart BA.
J Neuroimmune Pharmacol. 2013 Jun;8(3):715-26.

Contact: